Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (GB:0K3W)
LSE:0K3W
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
0.05Same Quarter Last Year
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -41.27%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Negative
The earnings call highlighted challenges with revenue decline and specific issues with GeneSight and hereditary cancer testing. However, some positive aspects included growth in prenatal testing and progress in the product pipeline. The company's guidance was revised downwards, indicating significant challenges ahead.Company Guidance
During the Myriad Genetics First Quarter 2025 earnings call, the company updated its 2025 financial guidance due to various challenges, including a decline in GeneSight test volumes and a softer than expected ramp in unaffected hereditary cancer testing. Myriad now projects annual revenue between $807 million and $823 million, down $35 million from the prior midpoint, and adjusted operating expenses between $555 million and $565 million, reduced by $25 million from the prior midpoint. Despite these challenges, Myriad reported strong performance in its prenatal testing, with a revenue growth of 11% year-over-year, and the company plans to launch new products such as the combined carrier screening and NIPS assay, PRECISE MRD, and AI-enabled Prolaris to drive future growth.Prenatal Testing Growth
Prenatal testing was a highlight in the quarter with revenue growth of 11% year-over-year, and 15% excluding SneakPeak, driven by strong demand for ForeSight and Prequel tests.
Oncology Test Volume Growth
Continued strong demand for the myRisk test for cancer patients, with test volume growth of 11% year-over-year.
Product Pipeline Progress
The company is on track to launch its first gene combined carrier screening and NIPS assay within the next couple of months, and the first AI-enabled Prolaris test by the end of the year.
Gross Margin Improvement
Despite the revenue decline, gross margins expanded by 50 basis points, delivering a 69% gross margin due to lab efficiencies.
---
GB:0K3W Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0K3W Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $7.32 | $4.48 | -38.81% |
Feb 24, 2025 | $14.30 | $11.97 | -16.26% |
Nov 07, 2024 | $17.95 | $17.84 | -0.59% |
Aug 06, 2024 | $26.48 | $27.66 | +4.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Myriad Genetics (GB:0K3W) report earnings?
Myriad Genetics (GB:0K3W) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Myriad Genetics (GB:0K3W) earnings time?
Myriad Genetics (GB:0K3W) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Myriad Genetics stock?
The P/E ratio of Myriad Genetics is N/A.
What is GB:0K3W EPS forecast?
GB:0K3W EPS forecast for the fiscal quarter 2025 (Q2) is >-0.01.
---